Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
U.S. FDA grants clearance for ER and PR image analysis system for breast cancer
June 6th, 2005
TriPath Imaging, Inc. (TPTH), and Ventana Medical Systems, Inc. (VMSI), announced TriPath Imaging has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Ventana Image Analysis System (VIAS) when used with tissues stained for estrogen receptor (ER) and progesterone eeceptor (PR). As previously announced, Ventana has entered into an agreement to market globally the Ventana-branded interactive histology image analysis system from TriPath Imaging. "This is clearly a gating event that sets the table for a Ventana launch of VIAS," said Paul R. Sohmer, MD, chairman, president, and CEO of TriPath Imaging. "The analysis of ER...
Source: Biotech Business Week (2005-06-06)
|
